| |
30 days before vaccination
|
Day of vaccination
|
30 days after vaccination
|
|---|
| |
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
Anti-TNF
|
40
|
7.8
|
32
|
6.2
|
40
|
7.8
|
|
Etanercept
|
18
|
3.5
|
12
|
2.3
|
18
|
3.5
|
|
Adalimumab
|
11
|
2.1
|
9
|
1.8
|
11
|
2.1
|
|
Infliximab
|
11
|
2.1
|
11
|
2.1
|
11
|
2.1
|
|
Other biologicsa
|
4
|
0.8
|
4
|
0.8
|
4
|
0.8
|
|
Nonbiologic DMARDs
| | | | | | |
|
Methotrexate
|
52
|
10.1
|
34
|
6.6
|
45
|
8.8
|
|
Sulfasalazine
|
16
|
3.1
|
13
|
2.5
|
16
|
3.1
|
|
Hydroxychloroquine
|
26
|
5.1
|
17
|
3.3
|
25
|
4.9
|
|
Azathioprine
|
1
|
0.2
|
1
|
0.2
|
1
|
0.2
|
|
Leflunomide
|
3
|
0.6
|
3
|
0.6
|
3
|
0.6
|
|
Cyclosporine
|
7
|
1.4
|
6
|
1.2
|
7
|
1.4
|
|
6-Mercaptopurine
|
5
|
1.0
|
3
|
0.6
|
5
|
1.0
|
|
Oral glucocorticoid
|
45
|
8.8
|
33
|
6.4
|
48
|
9.3
|
- DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aThe categories (columns) are not exclusive (for example, a patient who used anti-TNF therapies continuously during the 60-day period would be counted in all three categories). bAbatacept, rituximab.
